S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:CYTO

Altamira Therapeutics - CYTO Stock Forecast, Price & News

$2.96
-0.03 (-1.00%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.93
▼
$3.05
50-Day Range
$2.76
▼
$6.06
52-Week Range
$2.70
▼
$43.00
Volume
22,401 shs
Average Volume
65,901 shs
Market Capitalization
$2.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYTO stock logo

About Altamira Therapeutics (NASDAQ:CYTO) Stock

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTO Stock News Headlines

January 27, 2023 | americanbankingnews.com
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Update
January 26, 2023 | nasdaq.com
Altamira: NASAR Interim Analysis Shows Superior Efficacy Of Bentrio In Seasonal Allergic Rhinitis
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 25, 2023 | seekingalpha.com
CYTO Altamira Therapeutics Ltd.
January 24, 2023 | markets.businessinsider.com
Dow Rises 80 Points; Altamira Therapeutics Shares Plunge
January 24, 2023 | finance.yahoo.com
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
January 10, 2023 | finance.yahoo.com
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
December 20, 2022 | finanznachrichten.de
Altamira Therapeutics Ltd: Altamira Therapeutics Provides Year-End 2022 Business Update
February 5, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
December 19, 2022 | finance.yahoo.com
Altamira Therapeutics Provides Year-End 2022 Business Update
December 2, 2022 | finance.yahoo.com
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia
December 1, 2022 | finanznachrichten.de
Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
November 30, 2022 | finance.yahoo.com
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
November 30, 2022 | finance.yahoo.com
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
November 22, 2022 | finance.yahoo.com
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability
November 10, 2022 | finance.yahoo.com
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
November 9, 2022 | finance.yahoo.com
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
November 8, 2022 | finance.yahoo.com
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
October 26, 2022 | finanznachrichten.de
Altamira Therapeutics Ltd: Altamira Therapeutics Announces Reverse Stock Split
October 24, 2022 | finance.yahoo.com
Altamira Therapeutics Announces Reverse Stock Split
October 21, 2022 | finance.yahoo.com
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
October 21, 2022 | investorplace.com
Why Is Altamira Therapeutics (CYTO) Stock Up 70% Today?
October 13, 2022 | finance.yahoo.com
Altamira Therapeutics to Participate at RNA Leaders USA Congress
October 3, 2022 | baystreet.ca
Altamira Inches Higher as Tests Continue
October 3, 2022 | finance.yahoo.com
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia
September 27, 2022 | finance.yahoo.com
Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
September 13, 2022 | finance.yahoo.com
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
See More Headlines
Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTO Company Calendar

Today
2/05/2023
Next Earnings (Estimated)
4/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTO
CUSIP
N/A
CIK
1601936
Web
www.aurismedical.com
Phone
(441) 295-5950
Fax
41-61-201-1351
Employees
14
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.20
Quick Ratio
0.18

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
31.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$18.75 per share
Price / Book
0.16

Miscellaneous

Outstanding Shares
750,000
Free Float
651,000
Market Cap
$2.22 million
Optionable
Optionable
Beta
1.34

Key Executives

  • Thomas Meyer
    Chairman & Chief Executive Officer
  • Covadonga Pañeda
    Chief Operating Officer
  • Marcel Gremaud
    Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













CYTO Stock - Frequently Asked Questions

How have CYTO shares performed in 2023?

Altamira Therapeutics' stock was trading at $4.85 at the start of the year. Since then, CYTO stock has decreased by 39.0% and is now trading at $2.96.
View the best growth stocks for 2023 here.

Are investors shorting Altamira Therapeutics?

Altamira Therapeutics saw a decline in short interest in January. As of January 15th, there was short interest totaling 18,800 shares, a decline of 49.9% from the December 31st total of 37,500 shares. Based on an average daily volume of 123,800 shares, the short-interest ratio is presently 0.2 days. Approximately 1.7% of the company's shares are sold short.
View Altamira Therapeutics' Short Interest.

When is Altamira Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 11th 2023.
View our CYTO earnings forecast.

When did Altamira Therapeutics' stock split?

Shares of Altamira Therapeutics reverse split on the morning of Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Altamira Therapeutics' stock symbol?

Altamira Therapeutics trades on the NASDAQ under the ticker symbol "CYTO."

Who are Altamira Therapeutics' major shareholders?

Altamira Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Altamira Therapeutics?

Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Altamira Therapeutics' stock price today?

One share of CYTO stock can currently be purchased for approximately $2.96.

How much money does Altamira Therapeutics make?

Altamira Therapeutics (NASDAQ:CYTO) has a market capitalization of $2.22 million and generates $70,000.00 in revenue each year.

How can I contact Altamira Therapeutics?

Altamira Therapeutics' mailing address is Bahnhofstrasse 21, Zug, Zug 6300. The official website for the company is www.aurismedical.com. The company can be reached via phone at (441) 295-5950, via email at investors@aurismedical.com, or via fax at 41-61-201-1351.

This page (NASDAQ:CYTO) was last updated on 2/5/2023 by MarketBeat.com Staff